Sleep Quality and its Association with Disease Severity in Psoriasis

Melikoğlu, Mehmet

doi:10.5152/eurasianjmed.2017.17132

Cited by 30 publications

(63 citation statements)

References 17 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poor sleep quality was found to be significantly associated with rosacea with a high coefficient (OR, 3.525; 95% CI, 2.759–4.519). Moreover, there is a positive association between the severity of rosacea and sleep quality in our investigation, which is similar to the previous reports showing a positive association between PSQI and the severity of atopic dermatitis and psoriasis 43,46,50 . Our finding indicated that poor sleep quality is associated with rosacea, as well as its severity.…”

Section: Discussionsupporting

confidence: 91%

“…In our results, approximately 52.3% of rosacea patients suffered poor sleep quality (PSQI, >5), which is a decent proportion even compared with psoriasis. Meanwhile, the PSQI score in the rosacea patients is 6.20 ± 3.40, approaching that in psoriasis, 43,46,50 much higher than that of healthy controls (3.95 ± 2.63). Six of the seven PSQI components were found to be significantly higher in the rosacea group in our research, which is more than those in psoriasis 46 .…”

Section: Discussionmentioning

confidence: 77%

“…Meanwhile, the PSQI score in the rosacea patients is 6.20 ± 3.40, approaching that in psoriasis, 43,46,50 much higher than that of healthy controls (3.95 ± 2.63). Six of the seven PSQI components were found to be significantly higher in the rosacea group in our research, which is more than those in psoriasis 46 . Poor sleep quality was found to be significantly associated with rosacea with a high coefficient (OR, 3.525; 95% CI, 2.759–4.519).…”

Section: Discussionmentioning

confidence: 77%

“…Sleep quality has been investigated in skin diseases such as psoriasis and atopic dermatitis 42–44 . A percentage of 38.2–60% of psoriatic patients presented poor sleep quality (PSQI, >5) 42,45–48 . The mean PSQI score varies 6.5–8.1 in psoriatic patients, 42,46,49 Three of the seven PSQI components, namely subjective sleep quality, habitual sleep efficiency and daytime dysfunction, were significantly elevated in psoriasis 46 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Relationship between rosacea and sleep

Wang

Xie

Gong

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Rosacea is a chronic facial skin disease involved in neurovascular dysregulation and neurogenic inflammation. Behavioral factors such as stress, anxiety, depression and sleep were identified to be associated with other inflammatory skin diseases. Few studies have reported sleep status in rosacea. Aiming to investigate the relationship between rosacea and sleep, a case-control survey was conducted, enrolling 608 rosacea patients and 608 sex-and age-matched healthy controls. Sleep quality was assessed through the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Diagnosis and severity grading of rosacea were evaluated under the standard guidelines of the National Rosacea Society. More rosacea patients (52.3%, n = 318) suffered poor sleep quality (PSQI, >5) than the healthy controls (24.0%, n = 146), displaying a much higher PSQI score (rosacea vs control, 6.20 vs 3.95). There was a strong association between sleep quality and rosacea (odds ratio [OR], 3.525; 95% confidence interval [CI], 2.759-4.519). Moreover, the severity of rosacea was also associated with sleep quality (OR, 1.847; 95% CI, 1.332-2.570). Single nucleotide polymorphisms in hydroxytryptamine receptor 2A and adrenoceptor-b1 genes, which are associated with sleep behaviour, were detected and revealed to be associated with rosacea. Furthermore, the LL-37-induced rosacea-like phenotype and sleep-deprivation mice models were applied, revealing that sleep deprivation aggravated the rosacea-like phenotype in mice, with higher expression of matrix metallopeptidase 9, Toll-like receptor 2, cathelicidin antimicrobial peptide and vascular endothelial growth factor. In conclusion, rosacea patients presented poorer sleep quality, as well as a higher propability of genetic background with sleep disturbance. In addition, poor sleep might aggravate rosacea through regulating inflammatory factors, contributing to a vicious cycle in the progression of disease. Logistic regression adjusted by sex, age and BMI. Bold indicates significance. Values of Scores of seven components of the PSQI and global PSQI score are shown as means AE standard deviation. Values of sleep quality (good, bad) are shown as n (%). CI, confidence interval; OR, odds ratio; PSQI, Pittsburgh Sleep Quality Index.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between rosacea and sleep

Wang

Xie

Gong

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The PSQI total score of 6.5 points for patients with HS in this study was significantly higher than for controls, and seems to be higher than among general populations evaluated in previous studies (28,29). Moreover, patients with other dermatoses, including AD and Ps, seem to have comparable mean PSQI scores, assessed as 7.0 and 7.0-9.2 points, respectively (21,30,31).…”

Section: Discussioncontrasting

confidence: 51%

Influence of Itch and Pain on Sleep Quality in Patients with Hidradenitis Suppurativa

Kaaz

Szepietowski²,

Matusiak³

2018

Acta Derm Venerol

View full text Add to dashboard Cite

There is a lack of data evaluating the influence of hidradenitis suppurativa-related subjective symptoms on sleep quality. The aim of this study was to assess the influence of itch and pain on sleep quality in 108 patients with hidradenitis suppurativa compared with 50 controls. The Athens Insomnia Scale (AIS) and Pittsburgh Sleep Quality Index (PSQI) were used to evaluate a spectrum of sleep disturbances. Mean ± standard deviation AIS and PSQI scores among patients with hidradenitis suppurativa vs. controls were assessed as 5.4 ± 4.3 vs. 5.5 ± 3.4 and 6.5 ± 3.6 vs. 3.1 ± 1.9 points, respectively. The presence of both itch and pain had a significant impact on the frequency of insomnia. Pain was a crucial factor responsible for poor sleep quality among patients with hidradenitis suppurativa; its presence significantly affected subjective sleep quality, sleep duration and daytime dysfunction. Itch and pain have an important impact on insomnia and sleep quality in patients with hidradenitis suppurativa.

show abstract

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

et al. 2022

View full text Add to dashboard Cite

Background Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for psoriasis that also address itch are needed. Objectives To report effects of roflumilast cream on itch-related outcomes from a Phase 2b trial. Methods Adults with chronic plaque psoriasis were randomized to roflumilast 0.3%, roflumilast 0.15%, or vehicle once-daily for 12 weeks. Psoriasis severity was assessed via the Investigator Global Assessment (IGA; a 5-point scale assessing plaque thickening, scaling, and erythema ranging from 0 [clear] to 4 [severe]) and ≥ 2 on a modified Psoriasis Area and Severity Index (PASI-HD, which combines severity of lesions and area affected, ranging from 0 [no disease] to 72 [maximal disease], with the actual percentage of the anatomical area involved in those patients with < 10% of anatomical area involved [e.g., 0.1 for 1% to 0.9 for 9%]). Itch was evaluated via Worst Itch Numeric Rating Scale (WI-NRS), Psoriasis Symptom Diary (PSD) Items 1 (severity of itch) and 2 (bother of itch), and itch-related sleep loss NRS scores. Post hoc correlation analyses between WI-NRS and PASI, WI-NRS and itch-related sleep loss, and WI-NRS and DLQI were also performed. Results Roflumilast-treated patients had significantly greater improvements than vehicle-treated patients in WI-NRS and PSD Items 1 and 2 beginning at Week 2 and in itch-related sleep loss Weeks 6 through 12. Among patients with baseline WI-NRS ≥ 6, significantly more patients achieved ≥ 4-point improvement with roflumilast than with vehicle as early as Week 2. Itch severity had low correlation with PASI while WI-NRS and IGA were not always aligned. Limitations The first assessment was at 2 weeks, limiting the ability to assess early onset of itch response. Conclusion Roflumilast cream improved itch and itch-related sleep loss associated with chronic plaque psoriasis. ClinicalTrials.gov identifier NCT03638258.

show abstract

Sleep Quality and its Association with Disease Severity in Psoriasis

Cited by 30 publications

References 17 publications

Relationship between rosacea and sleep

Relationship between rosacea and sleep

Influence of Itch and Pain on Sleep Quality in Patients with Hidradenitis Suppurativa

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

Contact Info

Product

Resources

About